Please login to the form below

Not currently logged in

Teva promotes Allan Oberman to take over from William Marth

Executive leadership changes also see Jill DeSimone join

Teva Allan ObermanTeva has made a number of changes to its executive leadership team, promoting Allan Oberman and appointing Jill DeSimone.

Oberman will oversee the Israel-based generics company's Americas business, taking over the role held by William Marth, who is stepping down as president and CEO of Teva Americas Generics.

Oberman was previously senior vice president of North America generic pharmaceuticals, and prior to that held a number of senior roles at the company since joining in 2000. He has also served as president of EMIA (Eastern Europe, Middle East, Israel and Africa), chief operating officer of the Teva International Group, and president and CEO of Teva Canada.

Meanwhile, Jill DeSimone joins Teva as senior vice president and general manager of Teva Global Women's Health, a newly-created post where she will oversee all aspects of the company's women's health franchise.

She comes to the company from Bristol-Myers Squibb, where she held various global leadership positions, most recently as senior vice president, US commercialisation excellence.

“These changes are part of our ongoing process to build a premier leadership team and reshape Teva,” said Dr Jeremy Levin, president and CEO of Teva. “Allan brings extensive experience in global generics to the company's Americas teams. Jill brings a great track record and many years of experience in building franchises in specialty medicine. 

The changes also see William Marth step down as president and CEO of Teva Americas with immediate effect and retire at the end of 2013, in the interim serving as a senior advisor to Teva's president and CEO Dr Jeremy Levin.

8th November 2012

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge